A Phase 2b Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24, or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 weeks of Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV) Infection

ID Number 08-1147

Principal Investigator(s)
Joseph A Odin

Department(s) or Division(s)
Liver Diseases

Description

The purpose of this study is to compare the safety, tolerability and effectiveness of the experimental drug GS-9190 along with Peginterferon Alfa 2a (PEG) and Ribavirin (RIBA) compared to using only PEG and RIBA for treatment of chronic hepatitis C virus (HCV) infection.



Contact Information
Joseph A. Odin, MD
joseph.odin@mountsinai.org

Recruiting Patients: No